An mRNA Breast Cancer Vaccine from Uğur Şahin and Özlem Türeci: Reducing the Risk of Recurrence
Reading tools
In this article
The 6-year data published by Uğur Şahin and his team demonstrated that mRNA vaccines can keep patients' immune systems on alert against cancer for years.
Why was this study needed? Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Because it lacks hormone receptors or the HER2 protein, it does not respond to targeted drugs or hormone therapies. Despite successful surgery and chemotherapy, the disease unfortunately recurs within the first few years in a substantial proportion of these patients. This groundbreaking study, published in Nature on February 18, 2026, was designed to demonstrate whether mRNA vaccines, produced specifically for mutations in each patient's own tumor, could establish lasting T-cell (immune) memory to prevent recurrence.
The immune system's new memory: the evolution of T cells
The findings provide striking evidence of how the immune system recognizes cancer through vaccination and does not forget it:
Strong T-cell response after vaccination 100% (14/14 patients)
Patients who remained disease-free for 6 years 78.5% (11/14 patients)
Very strong T-cell responses that developed from scratch against multiple cancer mutations (neoantigens) were detected in the blood of almost all vaccinated patients. This was not merely a temporary reaction: without additional booster doses, the response remained functional for years.
A large proportion of T cells were found to have become killer (cytotoxic) cells ready for action and stem-cell-like memory cells that provide long-term protection. This means establishing an army that stands constant guard against cancer reappearing in the body.
Clinical outcomes: how does the tumor escape?
After a median follow-up of 5 years, 11 patients remained disease-free, while the profiles of the 3 patients who experienced recurrence offer valuable lessons for the scientific community:
- Weak response: The patient with the weakest T-cell response to the vaccine experienced recurrence but subsequently recovered after a complete response to standard immunotherapy (anti-PD-1).
- Immune escape: In the other cases, the tumor was found to have developed mechanisms to hide from the immune system (loss of MHC class I).
These data herald a future in which personalized mRNA vaccines become a much more formidable treatment protocol, used not only alone but in combination with other immunotherapy drugs (checkpoint inhibitors).
50 frequently asked questions about triple-negative breast cancer and mRNA vaccines
This section has been prepared to help you better understand the study findings and the new era in TNBC treatment.
Basic information and TNBC (1-10)
1. What exactly is triple-negative breast cancer (TNBC)? It is an aggressive type of breast cancer that lacks estrogen and progesterone receptors and the HER2 protein, and therefore does not respond to hormone therapies.
2. Why is it called triple-negative? It is named this way because all three of the most common receptors that drive cancer growth are absent from this tumor.
3. Why is TNBC considered more dangerous than other types? It is more dangerous because of its rapid growth, tendency to metastasize at an early stage, and limited treatment options.
4. When is the risk of recurrence highest in TNBC? The risk of recurrence usually peaks within the first 3 years after diagnosis.
5. Can this type of cancer be hereditary? Yes. Women who carry a BRCA1 gene mutation are particularly more likely to develop TNBC.
6. What does standard TNBC treatment include? It includes surgery, chemotherapy and, in some cases, radiotherapy and standard immunotherapies.
7. Are targeted drugs available for TNBC? Not in the standard sense, but antibody-drug conjugates (ADCs) and immunotherapies have begun to be used in recent years.
8. What are survival rates like for patients with TNBC? Success rates are high when it is detected at an early stage, but treatment becomes much more difficult if it recurs.
9. What does adjuvant treatment mean? It is protective treatment given after surgery to eliminate microscopic cells that may have been left behind.
10. Why is a vaccine being developed for TNBC? It is being developed to permanently eliminate the risk of recurrence, which remains high despite chemotherapy, by training the immune system.
mRNA vaccine technology and neoantigens (11-20)
11. What is a personalized mRNA cancer vaccine? It is a tailor-made vaccine produced specifically for each patient according to the mutations in their own tumor.
12. What is a neoantigen? These are mutated proteins found only in cancer cells and recognized as foreign by the immune system.
13. What role does mRNA technology play in cancer vaccines? It acts as a messenger carrying the genetic code (instructions) the body needs to recognize cancer cells.
14. Is this a therapeutic vaccine or a preventive one? In this study, it is a therapeutic vaccine used to prevent recurrence after surgery.
15. Is the same vaccine given to every patient? No. A completely different vaccine is produced using genetic data (NGS) obtained from each patient's tumor.
16. How many different mutations can a vaccine target? In this study by Uğur Şahin, 20 different neoantigens were targeted per patient.
17. How is the vaccine administered? The mRNA, enclosed in liposomal nanoparticles, is administered to the patient through a vein (intravenously).
18. How long does vaccine production take? In the study, it took an average of 69 days (approximately 2 months). The aim is to shorten this period in the future.
19. Does this vaccine harm healthy cells? No. Because the vaccine targets mutations specific to cancer cells, healthy tissues are protected.
20. Do mRNA vaccines alter our DNA? No. mRNA does not enter the nucleus or interact with DNA; it performs its task and is quickly broken down.
Study design and methodology (21-30)
21. How many patients were involved in the study? 14 patients with early-stage TNBC were enrolled and followed.
22. How were patients selected? Patients who had undergone surgery and completed standard chemotherapy but remained at high risk of recurrence were selected.
23. Was MRD (ctDNA) testing used in the study? It was not used as a selection criterion, but it is important for recurrence monitoring within the scientific framework of the research.
24. How many vaccine doses were administered? Patients received a total of 8 vaccine doses (at weekly and two-weekly intervals).
25. How long did the study last? Patients were followed for a median of 62 months (more than 5 years).
26. What does a de novo T-cell response mean? It means that vaccination enables the immune system to produce soldiers from scratch against cancer cells it has never recognized before.
27. How was the vaccine's safety tested? Adverse effects (side effects) were closely monitored, and most were found to be mild.
28. What is BioNTech's role in this study? It is the main organization that developed the vaccine platform and conducted the study.
29. Which genomic methods were used in the study? Mutations were identified using whole-exome sequencing (WES) and RNA sequencing.
30. Why was this called an umbrella study? Because it was a broad protocol testing the safety of several different types of mRNA vaccines simultaneously.
The immune system and T-cell responses (31-40)
31. How does the vaccine affect T cells? The vaccine shows T cells the specific mutations on the surface of cancer cells, preparing them to attack.
32. Why are memory T cells important? If cancer recurs years later, they immediately alert the system, enabling it to eliminate the tumor before it grows.
33. What do TCF-1-positive cells represent? They represent self-renewing, long-lived memory cells with stem-cell-like properties.
34. How long does the immune response last after vaccination? In this study, the immune response was demonstrated to persist for up to 6 years without booster doses.
35. What is the difference between CD4 and CD8 cells? CD8 cells are the killers that directly destroy cancer, while CD4 cells are the helpers that coordinate the system.
36. Does the vaccine exhaust the immune system? No. Instead of exhausting the system, the vaccine increases its efficiency by showing it a new, specific target.
37. What is immune escape? It is when cancer cells mutate over time and begin hiding from the immune system's radar.
38. What does loss of MHC class I mean? It means tumor cells destroy the identity card that allows the immune system to recognize them, becoming invisible.
39. Is the vaccine sufficient on its own? It is sufficient for some patients, but others may require a combination with immunotherapy (anti-PD-1).
40. What do cytotoxic effector cells do? Like soldiers ready for action, they pierce and destroy the cancer cells they encounter.
Clinical outcomes and future projections (41-50)
41. How many of the 14 patients remained free of recurrence? At the end of 6 years of follow-up, 11 patients had remained completely disease-free and without recurrence.
42. What happened to the patients whose cancer recurred? One recovered completely with additional immunotherapy, while the others continued to fight the disease because of the tumor's escape mechanisms.
43. What are the most common side effects after vaccination? Mild fever, headache, fatigue and chills (flu-like symptoms).
44. When will this vaccine become generally available? Phase 2 and Phase 3 studies are currently ongoing; approval is expected within a few years.
45. Could it also be used in other types of breast cancer? Yes. Research is ongoing for all types of breast cancer with a suitable mutational burden.
46. Will the vaccine replace chemotherapy? For now, it is used to reinforce chemotherapy's effects and prevent recurrence rather than replace it.
47. Could people with a BRCA mutation benefit from this vaccine? Yes, but as observed in the study, caution is needed regarding the risk of a new tumor developing in these patients.
48. How much will the vaccine cost? Because production is personalized, it may initially be costly, but access will improve as the technology develops.
49. What is Uğur Şahin and Özlem Türeci's main message from this study? That mRNA vaccines provide lasting immunity against cancer and are a vital tool for preventing recurrence.
50. What hope do these results offer patients with TNBC? They show that, against this cancer once described as having no target, the most precise target can now be identified from the patient's own genetics.
DrOZDOGAN Academy Commentary
mRNA vaccines: a turning point in cancer treatment
For an aggressive disease such as triple-negative breast cancer, producing a vaccine based on each patient's own genetic code rather than settling for standard treatment alone was one of our greatest aspirations in oncology. This study demonstrated how durable and powerful a weapon mRNA technology can be not only against COVID-19 but also in the long-term fight against cancer.
In particular, memory T cells remaining active in the blood for 6 years show that it may be possible to establish an insurance system enabling the body to protect itself against cancer recurrence. Combined with new MRD-focused studies, we believe tailor-made vaccines for each patient will become an essential part of routine practice in the near future.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.